BRIEF-Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran

Reuters
08 Apr
BRIEF-Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran

April 8 (Reuters) - Avidity Biosciences Inc RNA.O:

  • AVIDITY BIOSCIENCES RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN FOR DELPACIBART ETEDESIRAN (DEL-DESIRAN) FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1

  • AVIDITY BIOSCIENCES INC - EXPECTS TO COMPLETE PHASE 3 HARBOR STUDY ENROLLMENT IN MID-2025

Source text: ID:nPn1rjtTba

Further company coverage: RNA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10